2026-02-26 11:04Revenue Growth - Total global revenues reached $1.5 billion and $5.3 billion for the fourth quarter and full year 2025, representing increases of 33% and 40% from the prior-year periods[5] - Global BRUKINSA revenues were $1.1 billion and $3.9 billion for the fourth quarter and full year 2025, reflecting growth of 38% and 49% compared to the prior-year periods[11] - Total revenues for the full year 2025 were $5,343,033, up 40.4% from $3,810,241 in 2024[32] - BeOne's product revenue for Q4 2025 reached $1,476,442, a 32.2% increase from $1,118,035 in Q4 2024[32] Profitability - GAAP net income for the fourth quarter and full year 2025 was $67 million and $287 million, an increase of $218 million and $932 million over the prior-year periods[10] - Adjusted net income for the fourth quarter and full year 2025 was $225 million and $918 million, representing increases of 1297% and 1771% compared to the prior-year periods[3] - BeOne reported a net income of $66,502 for Q4 2025, a turnaround from a net loss of $151,881 in Q4 2024[32] - GAAP net income for Q4 2025 was $66,502, compared to a loss of $151,881 in Q4 2024, indicating a significant recovery[38] - Adjusted earnings per share (EPS) for Q4 2025 was $0.16, up from $0.01 in Q4 2024, reflecting improved profitability[39] Cash Flow - Free cash flow for the fourth quarter of 2025 was $380 million, an increase of $397 million over the prior-year period, while full year free cash flow was $942 million, up $1.6 billion[13] - Free cash flow for Q4 2025 was $379,825, a substantial increase from a negative $17,320 in Q4 2024, demonstrating strong cash generation capabilities[40] Expenses - Research and development expenses for the fourth quarter of 2025 were $615 million, a 14% increase from the prior-year period[8] - Selling, general and administrative expenses for the fourth quarter of 2025 were $555 million, a 10% increase from the prior-year period[9] - Total GAAP research and development expenses for 2025 were $2,145,868, up from $1,953,295 in 2024, indicating increased investment in innovation[38] - Total adjusted operating expenses for 2025 were $3,599,097, compared to $3,218,232 in 2024, indicating a rise in operational costs associated with growth initiatives[38] Gross Margin - Gross margin as a percentage of global product sales for the fourth quarter and full year 2025 was 90.4% and 87.3%, compared to 85.6% and 84.3% in the prior-year periods[7] - The company expects to achieve a gross margin percentage improvement as it scales its operations and product offerings[29] - Adjusted cost of sales for products in Q4 2025 was $137,403, slightly down from $141,288 in Q4 2024, reflecting cost management efforts[38] Clinical Trials and Product Development - The company presented significant clinical trial results for BRUKINSA and TEVIMBRA, confirming sustained benefits for patients with chronic lymphocytic leukemia and HER2-positive gastroesophageal adenocarcinoma[15] - The company plans to submit supplemental Biologics License Applications for TEVIMBRA in the U.S. and China in 1H 2026[24] - BeOne is set to initiate a Phase 3 trial for Sonrotoclax in 2H 2026, targeting adult patients with R/R multiple myeloma[24] Financial Health - The company’s cash, cash equivalents, and restricted cash increased to $4,609,647 as of December 31, 2025, compared to $2,638,747 in 2024[34] - BeOne's total assets grew to $8,188,573 in 2025, up from $5,920,910 in 2024, indicating strong financial health[34] Operational Turnaround - The company reported a GAAP loss from operations of $79,425 in Q4 2024, which improved to a profit of $185,035 in Q4 2025, showcasing operational turnaround[38] - The impairment of equity investments added $75,626 to the adjusted net income for 2025, highlighting the impact of market conditions on investment valuations[38] - The company recorded share-based compensation expenses of $510,247 for the full year 2025, compared to $441,793 in 2024, reflecting increased employee incentives[38]